CONTEXT: Glucagon-like peptide 1 (GLP-1), an insulinotropic peptide released into the circulation from intestinal enteroendocrine cells, is considered a hormonal mediator of insulin secretion. However, the physiological actions of circulating GLP-1 have been questioned because of the short half-life of the active peptide. Moreover, there is mounting evidence for localized, intra-islet mediation of GLP-1 receptor (GLP-1r) signaling including a role for islet dipeptidyl-peptidase 4 (DPP4). OBJECTIVE: To determine whether GLP-1r signaling contributes to insulin secretion in the absence of enteral stimulation and increased plasma levels, and whether this is affected by DPP4. METHODS: Single-site study conducted at an academic medical center of 20 nondiabetic subjects and 13 subjects with type 2 diabetes. This was a crossover study in which subjects received either a DPP4 inhibitor (DPP4i; sitagliptin) or placebo on 2 separate days. On each day they received a bolus of intravenous (IV) arginine during sequential 60-minute infusions of the GLP-1r blocker exendin[9-39] (Ex-9) and saline. The main outcome measures were arginine-stimulated secretion of C-Peptide (C-PArg) and insulin (InsArg). RESULTS: Plasma GLP-1 remained at fasting levels throughout the experiments and IV arginine stimulated both α- and β-cell secretion in all subjects. Ex-9 infusion reduced C-PArg in both the diabetic and nondiabetic groups by ~14% (P < .03 for both groups). Sitagliptin lowered baseline glycemia but did not affect the primary measures of insulin secretion. However, a significant interaction between sitagliptin and Ex-9 suggested more GLP-1r activation with DPP4i treatment in subjects with diabetes. CONCLUSION: GLP-1r activation contributes to β-cell secretion in diabetic and nondiabetic people during α-cell activation, but in the absence of increased circulating GLP-1. These results are compatible with regulation of β-cells by paracrine signals from α-cells. This process may be affected by DPP4 inhibition.
CONTEXT: Glucagon-like peptide 1 (GLP-1), an insulinotropic peptide released into the circulation from intestinal enteroendocrine cells, is considered a hormonal mediator of insulin secretion. However, the physiological actions of circulating GLP-1 have been questioned because of the short half-life of the active peptide. Moreover, there is mounting evidence for localized, intra-islet mediation of GLP-1 receptor (GLP-1r) signaling including a role for islet dipeptidyl-peptidase 4 (DPP4). OBJECTIVE: To determine whether GLP-1r signaling contributes to insulin secretion in the absence of enteral stimulation and increased plasma levels, and whether this is affected by DPP4. METHODS: Single-site study conducted at an academic medical center of 20 nondiabetic subjects and 13 subjects with type 2 diabetes. This was a crossover study in which subjects received either a DPP4 inhibitor (DPP4i; sitagliptin) or placebo on 2 separate days. On each day they received a bolus of intravenous (IV) arginine during sequential 60-minute infusions of the GLP-1r blocker exendin[9-39] (Ex-9) and saline. The main outcome measures were arginine-stimulated secretion of C-Peptide (C-PArg) and insulin (InsArg). RESULTS: Plasma GLP-1 remained at fasting levels throughout the experiments and IV arginine stimulated both α- and β-cell secretion in all subjects. Ex-9 infusion reduced C-PArg in both the diabetic and nondiabetic groups by ~14% (P < .03 for both groups). Sitagliptin lowered baseline glycemia but did not affect the primary measures of insulin secretion. However, a significant interaction between sitagliptin and Ex-9 suggested more GLP-1r activation with DPP4i treatment in subjects with diabetes. CONCLUSION: GLP-1r activation contributes to β-cell secretion in diabetic and nondiabetic people during α-cell activation, but in the absence of increased circulating GLP-1. These results are compatible with regulation of β-cells by paracrine signals from α-cells. This process may be affected by DPP4 inhibition.
Authors: Rayner Rodriguez-Diaz; R Damaris Molano; Jonathan R Weitz; Midhat H Abdulreda; Dora M Berman; Barbara Leibiger; Ingo B Leibiger; Norma S Kenyon; Camillo Ricordi; Antonello Pileggi; Alejandro Caicedo; Per-Olof Berggren Journal: Cell Metab Date: 2018-03-06 Impact factor: 27.287
Authors: Gary A Herman; Cathy Stevens; Kristien Van Dyck; Arthur Bergman; Bingming Yi; Marina De Smet; Karen Snyder; Deborah Hilliard; Michael Tanen; Wesley Tanaka; Amy Q Wang; Wei Zeng; Donald Musson; Gregory Winchell; Michael J Davies; Steven Ramael; Keith M Gottesdiener; John A Wagner Journal: Clin Pharmacol Ther Date: 2005-12 Impact factor: 6.875
Authors: Lu Zhu; Diptadip Dattaroy; Jonathan Pham; Lingdi Wang; Luiz F Barella; Yinghong Cui; Kenneth J Wilkins; Bryan L Roth; Ute Hochgeschwender; Franz M Matschinsky; Klaus H Kaestner; Nicolai M Doliba; Jürgen Wess Journal: JCI Insight Date: 2019-04-23
Authors: David A D'Alessio; Amanda M Denney; Linda M Hermiller; Ronald L Prigeon; Julie M Martin; William G Tharp; Monica Liqueros Saylan; Yanling He; Beth E Dunning; James E Foley; Richard E Pratley Journal: J Clin Endocrinol Metab Date: 2008-10-28 Impact factor: 5.958
Authors: Sarah M Gray; Andrew L Hoselton; Radha Krishna; Cris A Slentz; David A D'Alessio Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134